Is Lanluma FDA Approved?

Last Updated On: May 9, 2025

The U.S. Food and Drug Administration (FDA) plays a pivotal role in regulating medical devices, including dermal fillers, to ensure they meet rigorous safety and efficacy standards. FDA approval is only granted after comprehensive evaluation of clinical data, making it a trusted benchmark for healthcare providers and patients alike.

Lanluma is a collagen-stimulating injectable made from poly-L-lactic acid (PLLA), designed to restore volume and improve skin texture through gradual collagen regeneration. Commonly used for facial rejuvenation and body contouring, Lanluma offers a non-surgical alternative for those seeking natural, long-lasting results.

In this article, we’ll explore Lanluma’s FDA approval status, break down its mechanism of action, and examine its expanding role in aesthetic medicine.

Key Takeaways

• Regulatory authorities have not approved Lanluma for use in the United States, so U.S.-based aesthetic practices cannot legally administer it.
• It holds CE certification in Europe, meaning it meets the European Union’s safety and performance standards for medical devices.
• Practitioners across CE-approved regions widely use Lanluma for facial rejuvenation and body contouring.
• Sculptra, a similar PLLA-based filler, holds FDA approval and continues to be the preferred option in U.S. markets for comparable indications.
• Clinicians must adhere to local regulations and provide thorough patient education on product approval status and treatment expectations.

About: Operating since 2016, Med Supply Solutions is known for being one of the industry’s top and trusted suppliers of cosmetic and viscosupplementation products. Contact our sales department for more information if you want to buy Lanluma Fillers online.  

LANLUMA V

$229.00

Tier pricing

Save 0.87%

3 or more

$227.00 each

Save 1.31%

11 or more

$226.00 each

Save 1.75%

21 or more

$225.00 each

Understanding the CE Marking of Lanluma in Europe

The CE marking signifies that a product meets the European Union’s safety, health, and environmental protection requirements. Lanluma’s CE certification confirms that it has undergone thorough evaluation and quality checks, ensuring it is safe and effective for aesthetic use. CE designation allows Lanluma to be legally marketed and administered throughout the European Economic Area (EEA).

In Europe, clinicians use Lanluma for various aesthetic procedures, including facial rejuvenation and body contouring treatments like the Lanluma bum lift. Its CE mark assures both practitioners and patients of its compliance with strict European health standards, further contributing to its growing popularity in non-surgical cosmetic enhancement.

Current FDA Approval Status and Regulatory Pathway for Lanluma

As of now, Lanluma is not FDA-approved for cosmetic use in the United States. The FDA approval process involves a comprehensive review of clinical data, manufacturing processes, and post-market safety plans to ensure a product’s reliability and effectiveness. Until such approval is granted, Lanluma cannot be legally marketed or administered in U.S. aesthetic practices.

To achieve FDA approval, the manufacturer must submit extensive clinical trial data demonstrating safety, efficacy, and consistency. This includes long-term outcome studies and real-world data on patient safety. Without FDA approval, practitioners must rely on alternatives already cleared for use by U.S. regulators.

Implications of Using Lanluma in Non-FDA-Approved Markets

In countries where Lanluma has not received FDA approval, its use raises several important considerations:

• Legal Compliance: Practitioners must follow local laws, which may restrict or prohibit the use of non-FDA-approved products.
• Liability Exposure: Administering unapproved injectables can increase legal risks, especially if patients experience complications.
• Patient Counseling: Clear, transparent communication is essential to ensure that patients understand the regulatory status and what it means for their safety and treatment outcomes.

Clinicians must evaluate the risk-benefit ratio carefully and maintain full compliance with local health authority guidelines.

Comparing Lanluma Regulatory Status with Products Like Sculptra

Sculptra, another poly-L-lactic acid (PLLA) filler, is FDA-approved for facial aesthetic indications in the United States. Its approval gives providers a clear, regulated pathway for safe use. In contrast, Lanluma, though CE-marked and approved in many other regions, lacks this FDA endorsement, restricting its availability in U.S. clinics.

That said, Lanluma’s performance in CE-certified markets has led many to compare it favorably with Sculptra in terms of treatment outcomes and durability. For patients asking how long Lanluma lasts, studies and real-world experience show results may extend up to two years, particularly when appropriate maintenance sessions are followed. This status positions Lanluma as a strong alternative for clinics operating in markets where it is approved.

Conclusion

Lanluma’s regulatory standing varies by region. In the European Union, its CE mark confirms adherence to strict safety and quality standards, making it a trusted option for non-surgical volume enhancement. Since Lanluma lacks FDA approval in the United States, U.S. practitioners must use approved alternatives like Sculptra for PLLA-based treatments.

For patients and providers outside the U.S., Lanluma remains a viable option—backed by clinical efficacy, a growing base of users, and positive treatment outcomes. Nonetheless, it is critical for practitioners to maintain regulatory awareness, disclose approval status transparently, and ensure patient safety through evidence-based guidance and informed consent.

FAQs

1. Is Lanluma FDA-approved for use in the United States?

No, Lanluma is not currently FDA-approved for use in the U.S. Practitioners should use FDA-approved alternatives within the United States.

2. What does CE marking mean for Lanluma?

CE marking indicates that Lanluma complies with European Union safety, health, and environmental protection standards, allowing its use within the European Economic Area.

3. Can Lanluma be used for body contouring procedures?

Yes, clinicians in approved regions use Lanluma for body contouring treatments, including the Lanluma bum lift, which offers gradual and natural-looking enhancements.

4. How long does Lanluma last?

The effects of Lanluma can last up to two years or more, depending on individual factors and treatment areas.

References

DA-approved dermal fillers. U.S. Food and Drug Administration website. Accessed April 25, 2025. https://www.fda.gov/medical-devices/aesthetic-cosmetic-devices/fda-approved-dermal-fillers 

Ballor G. CE Marking, Business, and European Market Integration. Business History Review. 2022;96(1):77-108. doi:10.1017/S0007680521000696

Amselem M, Fatsea D, Forte R, Hasenöhrl C, Haus A, Salaabian A. Safety and effectiveness results of an innovative injectable poly‐L‐lactic acid‐based collagen stimulator (Lanluma®)—Clinical outcomes at 9 months in a post‐market study. Journal of Cosmetic Dermatology. Published online September 4, 2024. doi:10.1111/jocd.16527

Christen MO. Collagen Stimulators in Body Applications: A Review Focused on Poly-L-Lactic Acid (PLLA). Clin Cosmet Investig Dermatol. 2022;15:997-1019. Published 2022 Jun 21. doi:10.2147/CCID.S359813